Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild Alzheimer's Disease
What is the purpose of this trial?
This study is designed to look at the safety, tolerability, and pharmacodynamic effects of LY2886721 given to people with mild cognitive impairment due to Alzheimer's Disease (AD) or mild Alzheimer's Disease, as well as studying the effect of LY2886721 on cerebrospinal fluid (CSF).
- Eli Lilly and Company
- Last Updated:
- Study HIC#: